Effects of IRF5 Lupus Risk Haplotype on Pathways Predicted to Influence B Cell Functions

Table 3

Genes exhibiting differential expression between risk and nonrisk cells in the canonical pathways identified through ingenuity pathway analysis. Fold up/down column is positive in the case that the gene expression is higher in the risk haplotype cells, and negative in the case that gene expression is higher in the nonrisk cells. PIK3CA: phosphoinositide-3-kinase, catalytic, alpha; RAC1: Ras-related C3 botulinum toxin substrate 1. *The IFNB1 gene is found in both the interferon and Toll-like receptor pathways.

Gene pathway	Gene symbol	Mock infected 16 hours				EBV live virus infected 16 hours
		Avg. nonrisk	Avg. risk	Ratio	Fold up/down	Avg. nonrisk	Avg. risk	Ratio	Fold up/down
Interferon	IFNB1*	104.95	3.89	0.04	−26.99	5.39	9.15	1.70	1.70
	STAT1	71.08	52.84	0.74	−1.35	184.29	244.12	1.32	1.32
	OAS1	56.04	84.55	1.51	1.51	49.87	107.78	2.16	2.16
	MX1	3179.14	5161.02	1.62	1.62	3409.35	6199.20	1.82	1.82
	IFNAR2	959.14	1637.11	1.71	1.71	1437.47	1094.97	0.76	−1.31
	IFITM1	439.88	944.41	2.15	2.15	2128.61	2602.68	1.22	1.22
Toll-like receptor	IFNB1*	104.95	3.89	0.04	−26.99	5.39	9.15	1.70	1.70
	FOS	116.48	53.84	0.46	−2.16	90.05	120.60	1.34	1.34
	MYD88	281.53	152.57	0.54	−1.85	181.06	226.62	1.25	1.25
	TNFAIP3	439.96	321.29	0.73	−1.37	728.35	377.23	0.52	−1.93
	TLR1	26.50	46.76	1.76	1.76	67.59	116.37	1.72	1.72
	LY96 (MD-2)	560.79	1274.32	2.27	2.27	1128.47	1208.54	1.07	1.07
	CD14	401.17	1272.53	3.17	3.17	139.53	450.09	3.23	3.23
B-Cell receptor	CD79B	2222.90	991.48	0.45	−2.24	797.14	827.44	1.04	1.04
	CD79A	41.32	19.08	0.46	−2.17	6526.62	5973.72	0.92	−1.09
	RAC1	1407.29	930.84	0.66	−1.51	4.36	2.64	0.61	−1.65
	MAPK9	105.87	71.02	0.67	−1.49	62.50	80.35	1.29	1.29
	AKT1	512.79	353.65	0.69	−1.45	13.02	6.74	0.52	−1.93
	NFKB2	6.44	4.85	0.75	−1.33	495.75	147.18	0.30	−3.37
	PIK3CA	25.86	40.05	1.55	1.55	79.96	49.71	0.62	−1.61
	NFAT5	123.74	222.63	1.80	1.80	5.14	2.70	0.52	−1.91
	GSK3B	68.58	123.65	1.80	1.80	177.23	91.07	0.51	−1.95